Mektovi (Binimetinib) for Melanoma

Overview
Mektovi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to be used in combination with encorafenib to treat people who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (change), as detected by an FDA-approved test. Mektovi is also known by its drug name, binimetinib.

Mektovi is a member of a class of drugs called kinase inhibitors. It works by inhibiting the activity of two proteins, MEK1 and MEK2, that play a critical role in the growth and development of certain types of cancer cells, including melanoma. By targeting these proteins, Mektovi helps slow the spread of the disease.

How do I take it?
Prescribing information states that Mektovi is usually taken orally (by mouth) as a tablet twice daily, along with encorafenib. 

Mektovi should be taken exactly as prescribed by a doctor.

Side effects
The FDA-approved label for Mektovi lists common side effects for Mektovi plus encorafenib including fatigue, nausea, diarrhea, vomiting, and abdominal pain.

Rare but serious side effects of Mektovi plus encorafenib include new primary cancers, cardiomyopathy (heart function problems), dangerous blood clots, eye problems, lung scarring, liver damage, muscle problems, hemorrhage (heavy bleeding), and fetal harm.

For more details about this treatment, visit:

Mektovi (Binimetinib) — Pfizer

Mektovi (Binimetinib) — PfizerMektovi — Drugs.com